Two structurally different rituximab-specific CD20 mimotope peptides reveal that rituximab recognizes two different CD20-associated epitopes

Journal of Immunology

Volumn 182, Issue 1, 2009, Pages 416-423

  Perosa, Federico ^a   Favoino, Elvira ^a   Vicenti, Chiara ^a   Guarnera, Andrea ^b   Racanelli, Vito ^a   De Pinto, Vito ^b   Dammacco, Franco ^a  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; CYCLOPEPTIDE; CYCLOPEPTIDE RP15 C; CYCLOPEPTIDE RP5 L; EPITOPE; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; PEPTIDE LIBRARY; RITUXIMAB; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY; PEPTIDE FRAGMENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY SPECIFICITY; ANTIGEN RECOGNITION; ARTICLE; BACTERIOPHAGE; CLONE; COMPUTER MODEL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOCHEMISTRY; MOUSE; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN STRUCTURE; ANIMAL; ANTIBODY COMBINING SITE; ANTIGEN PRESENTATION; BAGG ALBINO MOUSE; BIOSYNTHESIS; CELL MEMBRANE; CHEMICAL STRUCTURE; CHEMISTRY; COMPARATIVE STUDY; COMPUTER SIMULATION; IMMUNOLOGY; METABOLISM; MOLECULAR MIMICRY; PROTEIN MOTIF; TUMOR CELL LINE;

AMINO ACID MOTIFS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGEN PRESENTATION; ANTIGENS, CD20; BINDING SITES, ANTIBODY; CELL LINE, TUMOR; COMPUTER SIMULATION; EPITOPES; FEMALE; HUMANS; MEMBRANE MICRODOMAINS; MICE; MICE, INBRED BALB C; MODELS, MOLECULAR; MOLECULAR MIMICRY; PEPTIDE FRAGMENTS; PEPTIDES, CYCLIC;

EID: 59849106372     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.182.1.416     Document Type: Article

References (41)

1. Deans, J. P., H. Li, and M. J. Polyak. 2002. CD20-mediated apoptosis: signalling through lipid rafts. Immunology 107: 176-182.
2. Leget, G. A., and M. S. Czuczman. 1998. Use of rituximab, the new FDA-approved antibody. Curr. Opin. Oncol. 10: 548-551.
3. Coiffier, B. 2006. Monoclonal antibody as therapy for malignant lymphomas. C. R. Biol. 329: 241-254.
4. Cheson, B. D., and J. P. Leonard. 2008. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N. Engl. J. Med. 359: 613-626.
5. Check, E. 2004. Mouse opens door for study of autoimmune diseases. Nature 428: 786.
6. Edwards, J. C., and G. Cambridge. 2006. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat. Rev. Immunol. 6: 394-403.
7. Bezombes, C., S. Grazide, C. Garret, C. Fabre, A. Quillet-Mary, S. Muller, J. P. Jaffrezou, and G. Laurent. 2004. Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains. Blood 104: 1166-1173.
8. Polyak, M. J., S. H. Tailor, and J. P. Deans. 1998. Identification of a cytoplasmic region of CD20 required for its redistribution to a detergent-insoluble membrane compartment. J. Immunol. 161: 3242-3248.
9. Teeling, J. L., W. J. Mackus, L. J. Wiegman, J. H. van den Brakel, S. A. Beers, R. R. French, M. T. van, S. Ebeling, T. Vink, J. W. Slootstra, P. W. Parren, et al. 2006. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J. Immunol. 177: 362-371.
10. Polyak, M. J., and J. P. Deans. 2002. Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure. Blood 99: 3256-3262.
11. Ernst, J. A., H. Li, H. S. Kim, G. R. Nakamura, D. G. Yansura, and R. L. Vandlen. 2005. Isolation and characterization of the B-cell marker CD20. Biochemistry 44: 15150-15158.
12. Glennie, M. J., R. R. French, M. S. Cragg, and R. P. Taylor. 2007. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol. Immunol. 44: 3823-3837.
13. Perosa, F., E. Favoino, M. A. Caragnano, and F. Dammacco. 2006. Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor. Blood 107: 1070-1077.
14. Binder, M., F. Otto, R. Mertelsmann, H. Veelken, and M. Trepel. 2006. The epitope recognized by rituximab. Blood 108: 1975-1978.
15. Roberts, W. K., P. O. Livingston, D. B. Agus, J. Pinilla-Ibarz, A. Zelenetz, and D. A. Scheinberg. 2002. Vaccination with CD20 peptides induces a biologically active, specific immune response in mice. Blood 99: 3748-3755.
16. Perosa, F., E. Favoino, M. A. Caragnano, and F. Dammacco. 2005. CD20 mimicry by mAb rituximab-specific linear peptide: a potential tool for active immunotherapy of autoimmune diseases. Ann. NY Acad. Sci. 1051: 672-683.
17. Eisenberg, R., and R. J. Looney. 2005. The therapeutic potential of anti-CD20 "what do B-cells do?" Clin. Immunol. 117: 207-213.
18. Popa, C., M. J. Leandro, G. Cambridge, and J. C. Edwards. 2007. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs. Rheumatology 46: 626-630.
19. Perosa, F., E. Favoino, C. Vicenti, F. Merchionne, and F. Dammacco. 2007. Identification of an antigenic and immunogenic motif expressed by two 7-mer rituximab-specific cyclic peptide mimotopes: implication for peptide-based active immunotherapy. J. Immunol. 179: 7967-7974.
20. Riemer, A. B., M. Klinger, S. Wagner, A. Bernhaus, L. Mazzucchelli, H. Pehamberger, O. Scheiner, C. C. Zielinski, and E. Jensen-Jarolim. 2004. Generation of peptide mimics of the epitope recognized by trastuzumab on the oncogenic protein Her-2/neu. J. Immunol. 173: 394-401.
21. Luo, W., J. C. Hsu, C. Y. Tsao, E. Ko, X. Wang, and S. Ferrone. 2005. Differential immunogenicity of two peptides isolated by high molecular weight-melanoma-associated antigen-specific monoclonal antibodies with different affinities. J. Immunol. 174: 7104-7110.
22. Wagner, S., C. Hafner, D. Allwardt, J. Jasinska, S. Ferrone, C. C. Zielinski, O. Scheiner, U. Wiedermann, H. Pehamberger, and H. Breiteneder. 2005. Vaccination with a human high molecular weight melanoma-associated antigen mimotope induces a humoral response inhibiting melanoma cell growth in vitro. J. Immunol. 174: 976-982.
23. Pashov, A. D., J. Plaxco, S. V. Kaveri, B. Monzavi-Karbassi, D. Harn, and T. Kieber-Emmons. 2006. Multiple antigenic mimotopes of HIV carbohydrate antigens: relating structure and antigenicity. J. Biol. Chem. 281: 29675-29683.
24. Li, H., L. M. Ayer, M. J. Polyak, C. M. Mutch, R. J. Petrie, L. Gauthier, N. Shariat, M. J. Hendzel, A. R. Shaw, K. D. Patel, and J. P. Deans. 2004. The CD20 calcium channel is localized to microvilli and constitutively associated with membrane rafts: antibody binding increases the affinity of the association through an epitope-dependent cross-linking-independent mechanism. J. Biol. Chem. 279: 19893-19901.
25. Michel, R. B., and M. J. Mattes. 2002. Intracellular accumulation of the anti-CD20 antibody 1F5 in B-lymphoma cells. Clin. Cancer Res. 8: 2701-2713.
26. Streicher, H. Z., F. Cuttitta, G. K. Buckenmeyer, H. Kawamura, J. Minna, and J. A. Berzofsky. 1986. Mapping the idiotopes of a monoclonal anti-myoglobin antibody with syngeneic monoclonal anti-idiotypic antibodies: detection of a common idiotope. J. Immunol. 136: 1007-1014.
27. 2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide. J. Immunol. 171: 1918-1926.
28. Perosa, F., R. Carbone, S. Ferrone, and F. Dammacco. 1990. Purification of human immunoglobulins by sequential precipitation with caprylic acid and ammonium sulphate. J. Immunol. Methods 128: 9-16.
29. Liu, S., C. Zhang, S. Liang, and Y. Zhou. 2007. Fold recognition by concurrent use of solvent accessibility and residue depth. Proteins 68: 636-645.
30. Du, J., H. Wang, C. Zhong, B. Peng, M. Zhang, B. Li, S. Huo, Y. Guo, and J. Ding. 2007. Structural basis for recognition of CD20 by therapeutic antibody rituximab. J. Biol. Chem. 282: 15073-15080.
31. Mintseris, J., B. Pierce, K. Wiehe, R. Anderson, R. Chen, and Z. Weng. 2007. Integrating statistical pair potentials into protein complex prediction. Proteins 69: 511-520.
32. Dell'Orco, D., M. Seeber, P. G. De Benedetti, and F. Fanelli. 2005. Probing fragment complementation by rigid-body docking: in silico reconstitution of calbindin D9k. J. Chem. Inf. Model 45: 1429-1438.
33. Jo, S., T. Kim, V. G. Iyer, and W. Im. 2008. CHARMM-GUI: a web-based graphical user interface for CHARMM. J. Comput. Chem. 29: 1859-1865.
34. Thanos, C. D., W. L. DeLano, and J. A. Wells. 2006. Hot-spot mimicry of a cytokine receptor by a small molecule. Proc. Natl. Acad. Sci. USA 103: 15422-15427.
35. Polyak, M. J., L. M. Ayer, A. J. Szczepek, and J. P. Deans. 2003. A cholesterol-dependent CD20 epitope detected by the FMC7 antibody. Leukemia 17: 1384-1389.
36. Bremer, E., B. ten Cate, D. F. Samplonius, N. Mueller, H. Wajant, A. J. Stel, M. Chamuleau, A. A. van de Loosdrecht, J. Stieglmaier, G. H. Fey, and W. Helfrich. 2008. Superior activity of fusion protein scFvRit:sFasL over co-treatment with rituximab and Fas agonists. Cancer Res. 68: 597-604.
37. Perosa, F., and S. Ferrone. 1989. Murine antiidiotypic monoclonal antibodies that bear the internal image of HLA-DR allospecificities. J. Clin. Invest. 84: 907-914.
38. Srinivasan, R., A. N. Houghton, and J. D. Wolchok. 2002. Induction of autoantibodies against tyrosinase-related proteins following DNA vaccination: unexpected reactivity to a protein paralogue. Cancer Immun. 2: 8.
39. Vanderlugt, C. L., and S. D. Miller. 2002. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat. Rev. Immunol. 2: 85-95.
40. Disis, M. L., V. Goodell, K. Schiffman, and K. L. Knutson. 2004. Humoral epitope-spreading following immunization with a HER-2/neu peptide based vaccine in cancer patients. J. Clin. Immunol. 24: 571-578.
41. Ghetie, M. A., M. Crank, S. Kufert, I. Pop, and E. Vitetta. 2006. Rituximab but not other anti-CD20 antibodies reverses multidrug resistance in 2 B lymphoma cell lines, blocks the activity of P-glycoprotein (P-gp), and induces P-gp to translocate out of lipid rafts. J. Immunother. 29: 536-544.